Scarica l'app Stockscreener
133.19
2.40%
3.12
Dopo l'orario di chiusura:
133.09
-0.10
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$130.07
Aprire:
$130
Volume 24 ore:
1.47M
Relative Volume:
0.90
Capitalizzazione di mercato:
$19.85B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
13.15
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
+4.62%
1M Prestazione:
+1.56%
6M Prestazione:
-11.21%
1 anno Prestazione:
-41.79%
Intervallo 1D:
$129.84
$134.63
Intervallo di 1 settimana:
$123.90
$134.75
Portata 52W:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
133.19 | 19.85B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
779.28 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.56 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.82 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
190.75 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.81 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com
Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum
Biogen Dips on Its Part in BRAVE Study - Baystreet.ca
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus
Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen
How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com
Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st
Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph
Biogen patents new HTT splicing modulators - BioWorld MedTech
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus
Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media
NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire
Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey
Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com
Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum
Biogen Requests to Dismiss Class Action Filed by Investors - TradingView
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat
Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus
Biogen: positive Phase 3 data in lupus - marketscreener.com
Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat
Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus
Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):